Kevin P. Kerns

Array ( [id] => 10474837 [patent_doc_number] => 20150359854 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2015-12-17 [patent_title] => 'INSULIN RECEPTOR INDUCED ELASTIN PRODUCTION' [patent_app_type] => utility [patent_app_number] => 14/733739 [patent_app_country] => US [patent_app_date] => 2015-06-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 20 [patent_figures_cnt] => 20 [patent_no_of_words] => 10149 [patent_no_of_claims] => 12 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14733739 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10459543 [patent_doc_number] => 20150344559 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2015-12-03 [patent_title] => 'ANTI-TNF-ALPHA GLYCOANTIBODIES AND USES THEREOF' [patent_app_type] => utility [patent_app_number] => 14/722775 [patent_app_country] => US [patent_app_date] => 2015-05-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 2 [patent_figures_cnt] => 2 [patent_no_of_words] => 18051 [patent_no_of_claims] => 32 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14722775 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10367083 [patent_doc_number] => 20150252089 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2015-09-10 [patent_title] => 'Modified Human Thymic Stromal Lymphopoietin' [patent_app_type] => utility [patent_app_number] => 14/717334 [patent_app_country] => US [patent_app_date] => 2015-05-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 12783 [patent_no_of_claims] => 18 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14717334 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10685828 [patent_doc_number] => 20160031974 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-02-04 [patent_title] => 'ANTIBODY MOLECULES HAVING SPECIFICITY FOR HUMAN 0X40' [patent_app_type] => utility [patent_app_number] => 14/697142 [patent_app_country] => US [patent_app_date] => 2015-04-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 18 [patent_figures_cnt] => 18 [patent_no_of_words] => 17803 [patent_no_of_claims] => 7 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14697142 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13278461 [patent_doc_number] => 10150802 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2018-12-11 [patent_title] => Superagonists, partial agonists and antagonists of interleukin-2 [patent_app_type] => utility [patent_app_number] => 15/305831 [patent_app_country] => US [patent_app_date] => 2015-04-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 28 [patent_figures_cnt] => 28 [patent_no_of_words] => 27390 [patent_no_of_claims] => 26 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 45 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15305831 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11436113 [patent_doc_number] => 20170037134 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-02-09 [patent_title] => 'Compositions and Methods for Treating Cytokine-Related Disorders' [patent_app_type] => utility [patent_app_number] => 15/305272 [patent_app_country] => US [patent_app_date] => 2015-04-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 13 [patent_figures_cnt] => 13 [patent_no_of_words] => 9368 [patent_no_of_claims] => 11 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15305272 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10476139 [patent_doc_number] => 20150361157 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2015-12-17 [patent_title] => 'SGP130/FC DIMERS' [patent_app_type] => utility [patent_app_number] => 14/689635 [patent_app_country] => US [patent_app_date] => 2015-04-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 3 [patent_figures_cnt] => 3 [patent_no_of_words] => 5580 [patent_no_of_claims] => 11 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14689635 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11491532 [patent_doc_number] => 20170065717 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-03-09 [patent_title] => 'Method for treating muscular dystrophy' [patent_app_type] => utility [patent_app_number] => 15/305342 [patent_app_country] => US [patent_app_date] => 2015-04-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 2 [patent_figures_cnt] => 2 [patent_no_of_words] => 3469 [patent_no_of_claims] => 6 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15305342 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11487091 [patent_doc_number] => 09593155 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2017-03-14 [patent_title] => 'Oxyntomodulin analogs' [patent_app_type] => utility [patent_app_number] => 14/686760 [patent_app_country] => US [patent_app_date] => 2015-04-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 27 [patent_figures_cnt] => 27 [patent_no_of_words] => 39932 [patent_no_of_claims] => 10 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 19 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14686760 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11729345 [patent_doc_number] => 20170190789 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-07-06 [patent_title] => 'Methods and Compositions for the Treatment of Ocular Diseases and Disorders' [patent_app_type] => utility [patent_app_number] => 15/302088 [patent_app_country] => US [patent_app_date] => 2015-04-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 1 [patent_figures_cnt] => 1 [patent_no_of_words] => 3431 [patent_no_of_claims] => 16 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15302088 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11901981 [patent_doc_number] => 09771404 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2017-09-26 [patent_title] => 'Multi-level specific targeting of cancer cells' [patent_app_type] => utility [patent_app_number] => 14/681355 [patent_app_country] => US [patent_app_date] => 2015-04-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 15038 [patent_no_of_claims] => 26 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 112 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14681355 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12043476 [patent_doc_number] => 09821057 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2017-11-21 [patent_title] => 'Anti-IL-6 antibody for use in the treatment of cachexia' [patent_app_type] => utility [patent_app_number] => 14/672543 [patent_app_country] => US [patent_app_date] => 2015-03-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 79 [patent_figures_cnt] => 79 [patent_no_of_words] => 114932 [patent_no_of_claims] => 1 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 168 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14672543 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11514337 [patent_doc_number] => 20170081412 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-03-23 [patent_title] => 'ANTIBODY-FYNOMER CONJUGATES' [patent_app_type] => utility [patent_app_number] => 15/126551 [patent_app_country] => US [patent_app_date] => 2015-03-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 61 [patent_figures_cnt] => 61 [patent_no_of_words] => 34423 [patent_no_of_claims] => 48 [patent_no_of_ind_claims] => 24 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15126551 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10347558 [patent_doc_number] => 20150232564 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2015-08-20 [patent_title] => 'REGULATING IL-4 AND IL-13 LEVELS BY BLOCKING HIGH AFFINITY BINDING BY IL-3, IL-5 AND GM-CSF TO THEIR COMMON RECEPTOR' [patent_app_type] => utility [patent_app_number] => 14/638579 [patent_app_country] => US [patent_app_date] => 2015-03-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 9 [patent_figures_cnt] => 9 [patent_no_of_words] => 20853 [patent_no_of_claims] => 24 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14638579 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10281650 [patent_doc_number] => 20150166647 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2015-06-18 [patent_title] => 'ANTIKINE ANTIBODIES THAT BIND TO MULTIPLE CC CHEMOKINES' [patent_app_type] => utility [patent_app_number] => 14/630112 [patent_app_country] => US [patent_app_date] => 2015-02-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 14 [patent_figures_cnt] => 14 [patent_no_of_words] => 33908 [patent_no_of_claims] => 29 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14630112 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11618351 [patent_doc_number] => 20170128539 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-05-11 [patent_title] => 'IL-2RBETA-SELECTIVE AGONISTS IN COMBINATION WITH AN ANTI-CTLA-4 ANTIBODY OR AN ANTI-PD-1 ANTIBODY' [patent_app_type] => utility [patent_app_number] => 15/120214 [patent_app_country] => US [patent_app_date] => 2015-02-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 20 [patent_figures_cnt] => 20 [patent_no_of_words] => 12371 [patent_no_of_claims] => 9 [patent_no_of_ind_claims] => 6 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15120214 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10483299 [patent_doc_number] => 20150368318 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2015-12-24 [patent_title] => 'MUTANTS OF INTERLEUKIN-1 RECEPTOR ANTAGONIST AND USES THEREOF' [patent_app_type] => utility [patent_app_number] => 14/620898 [patent_app_country] => US [patent_app_date] => 2015-02-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 5 [patent_figures_cnt] => 5 [patent_no_of_words] => 22207 [patent_no_of_claims] => 11 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14620898 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13051505 [patent_doc_number] => 10047133 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2018-08-14 [patent_title] => Glycosaminoglycan-antagonising fusion proteins and methods of using same [patent_app_type] => utility [patent_app_number] => 15/113394 [patent_app_country] => US [patent_app_date] => 2015-01-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 17 [patent_figures_cnt] => 20 [patent_no_of_words] => 10698 [patent_no_of_claims] => 10 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 58 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15113394 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10254992 [patent_doc_number] => 20150139989 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2015-05-21 [patent_title] => 'ANTIBODY RECOGNIZING HUMAN LEUKEMIA INHIBITORY FACTOR (LIF) AND USE OF ANTI-LIF ANTIBODIES IN THE TREATMENT OF DISEASES ASSOCIATED WITH UNWANTED CELL PROLIFERATION' [patent_app_type] => utility [patent_app_number] => 14/589033 [patent_app_country] => US [patent_app_date] => 2015-01-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 9 [patent_figures_cnt] => 9 [patent_no_of_words] => 14175 [patent_no_of_claims] => 19 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14589033 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12017999 [patent_doc_number] => 09810696 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2017-11-07 [patent_title] => 'PGLYRP2 biomarker in idiopathic pneumonia syndrome' [patent_app_type] => utility [patent_app_number] => 14/571067 [patent_app_country] => US [patent_app_date] => 2014-12-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 5 [patent_figures_cnt] => 5 [patent_no_of_words] => 17517 [patent_no_of_claims] => 3 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 117 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14571067 [rel_patent_id] =>[rel_patent_doc_number] =>)